Latest Conference Articles

March 6th 2014, 3:46pm

PER® Miami Breast Cancer Conference

Melvin J. Silverstein, MD, FACS, director, Breast Program Hoag Memorial Hospital, professor of surgery, Keck School of Medicine, University of Southern California, describes oncoplastic surgery.

March 6th 2014, 12:35pm

PER® Miami Breast Cancer Conference

Hyman B. Muss, MD, discusses optimizing the administration of endocrine therapies with or without mTOR inhibitors for patients with HR-positive metastatic breast cancer

February 3rd 2014, 12:36pm

Genitourinary Cancers Symposium (ASCO GU)

Tomasz Beer, MD, FACP, professor of Medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, discusses the treatment of metastatic castration-resistant prostate cancer (mCRPC) with abiraterone and enzalutamide as it relates to results from the PREVAIL study.

February 3rd 2014, 11:05am

Genitourinary Cancers Symposium (ASCO GU)

Sophie D. Fosså, MD, PhD, professor, Department of Oncology, Oslo University Hospital, Norway, discusses a trial analyzing the benefit for radiotherapy/antiandrogen combination in men with locally advanced prostate cancer.

February 3rd 2014, 10:22am

Genitourinary Cancers Symposium (ASCO GU)

High tumor expression of the protein PD-L1 is independently associated with shorter OS in patients with mRCC receiving treatment with VEGF-targeted therapy.

February 1st 2014, 11:13am

Genitourinary Cancers Symposium (ASCO GU)

Two new combinations demonstrated activity in refractory or advanced, previously untreated urothelial carcinoma in phase II evaluations.

February 1st 2014, 11:04am

Genitourinary Cancers Symposium (ASCO GU)

Robert Figlin, MD, FACP, discusses updated data on the ADAPT trial, which is an ongoing international phase III randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment in metastatic renal cell carcinoma (mRCC)

February 1st 2014, 10:08am

Genitourinary Cancers Symposium (ASCO GU)

Survival, measured as either disease-specific survival or relative conditional survival, has not improved for patients with metastatic urothelial carcinoma despite increasing use of second-line therapies with no formal indication in this setting.

February 1st 2014, 9:06am

Genitourinary Cancers Symposium (ASCO GU)

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses validating a whole-blood RNA prognostic signature in mCRPC.

January 31st 2014, 4:44pm

Genitourinary Cancers Symposium (ASCO GU)

Prednisone, when used in concert with other therapies for the treatment of metastatic castration-resistant prostate cancer, does not raise the risk for severe toxicities, nor does it affect overall survival.

January 31st 2014, 11:07am

Genitourinary Cancers Symposium (ASCO GU)

Patients with metastatic castration-resistant prostate cancer (mCRPC) who have detectable serum androgen levels despite treatment with ketoconazole experience prostate-specific antigen (PSA) response to subsequent abiraterone acetate

January 31st 2014, 9:25am

Genitourinary Cancers Symposium (ASCO GU)

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses changes in relative conditional survival in metastatic urothelial carcinoma.

January 31st 2014, 8:32am

Genitourinary Cancers Symposium (ASCO GU)

Extended follow-up of patients with castration-resistant prostate cancer (CRPC) and bone metastases randomized to radium-223 dichloride (Xofigo) in the phase III ALSYMPCA study revealed a continued low incidence of myelosuppression and no association with secondary malignancies.

January 31st 2014, 7:02am

Genitourinary Cancers Symposium (ASCO GU)

Leonard Gomella, MD, from the Kimmel Cancer Center Network, Thomas Jefferson University Hospital, provides an update on the dendritic cell cancer vaccine sipuleucel-T in castration-resistant prostate cancer.

January 30th 2014, 10:57am

Genitourinary Cancers Symposium (ASCO GU)

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses the androgen receptor inhibitor ODM-201, which is used to treat castration-resistant prostate cancer.

January 30th 2014, 10:06am

Genitourinary Cancers Symposium (ASCO GU)

Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses the results of a study that evaluated the safety of abiraterone acetate combined with docetaxel in patients with metastatic castration-resistant prostate cancer that were presented at the 2014 Genitourinary Cancer Symposium in San Francisco.

January 29th 2014, 2:46pm

Genitourinary Cancers Symposium (ASCO GU)

An updated analysis, conducted after 11 years of observation, demonstrated continued improved outcomes with the addition of radiotherapy to oral antiandrogen therapy in men with locally advanced prostate cancer.

January 28th 2014, 3:34pm

Genitourinary Cancers Symposium (ASCO GU)

The androgen-receptor blocker enzalutamide (Xtandi) improves survival by nearly 30% in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) and delays progression of their disease by more than 80%

January 28th 2014, 3:03pm

Genitourinary Cancers Symposium (ASCO GU)

A vast, pooled retrospective analysis has demonstrated that the use of ASIs may significantly improve survival outcomes in patients with mRCC.

January 28th 2014, 3:03pm

Genitourinary Cancers Symposium (ASCO GU)

The premature termination of clinical trials in the oncology setting is a problem that continues to vex researchers.